Safety Study of Low Dose Interleukin 2 (IL-2) Plus PEG-IFN/RBV In Chronic Hepatitis C Virus Genotype I

NCT00277758 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

18

Enrollment

OTHER

Sponsor class

Stopped Insufficient rate of volunteer accrual.

Conditions

Hepatitis C

Interventions

BIOLOGICAL: Interleukin 2
DRUG: Ribavirin
BIOLOGICAL: Pegylated Interferon Alpha
BIOLOGICAL: Inteleukin-2
DRUG: Ribavirin + Pegylated interferon-alpha

Sponsor

Weill Medical College of Cornell University

Collaborators

[object Object]